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Abstract
The wild-type CCK2 receptor is expressed in many gastrointestinal and lung tumors. A splice
variant of the CCK2 receptor with retention of intron 4 (CCK2Ri4sv) showing constitutive activity
associated with increased tumor growth was described in few colorectal, pancreatic, and gastric
cancers. Given the potential functional and clinical importance of this spliceoform, its occurrence
was quantitatively characterized in a broad collection of 81 gastrointestinal and lung tumors,
including insulinomas, ileal carcinoids, gastrointestinal stromal tumors (GIST), gastric, colorectal,
and pancreatic ductal adenocarcinomas, cholangiocellular and hepatocellular carcinomas, small
cell lung cancers (SCLC), non-SCLC, and bronchopulmonary carcinoids, as well as 21 samples of
corresponding normal tissues. These samples were assessed for transcript expression of total
CCK2 receptor, wild-type CCK2 receptor, and CCK2Ri4sv with end-point and real-time RT-PCR,
and for total CCK2 receptor protein expression on the basis of receptor binding with in vitro
receptor autoradiography. Wild-type CCK2 receptor transcripts were found in the vast majority of
tumors and normal tissues. CCK2Ri4sv mRNA expression was present predominantly in
insulinomas (incidence 100%), GIST (100%), and SCLC (67%), but rarely in pancreatic,
colorectal, and gastric carcinomas and non-SCLC. It was not found in wild-type CCK2 receptor
negative tumors or any normal tissues tested. CCK2Ri4sv transcript levels in individual tumors
were low, ranging from 0.02% to 0.14% of total CCK2 receptor transcripts. In conclusion, the
CCK2Ri4sv is a marker of specific gastrointestinal and lung tumors. With its high selectivity for
and high incidence in SCLC and GIST, it may represent an attractive clinical target.
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Introduction
The cholecystokinin type 2 (CCK2) receptor is a G protein-coupled, 7 transmembrane
domain receptor. Physiologically, it is expressed mainly in the brain and gastrointestinal
tract where it mediates the effects of gastrin on gastric acid secretion and epithelial and
endocrine cell growth [1]. The CCK2 receptor is also a cancer biomarker of increasing
clinical importance. It is expressed by a wide variety of tumors in and outside the
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gastrointestinal tract. It is present at especially high levels in medullary thyroid carcinomas,
small cell lung cancer (SCLC), gastrointestinal stromal tumors (GIST), and insulinomas [2].
This has led to the successful development of clinical applications using radioactive CCK2
receptor ligands for imaging and targeted radiotherapy of some of these tumors [3].
Conversely, the effects of the CCK2 receptor on proliferation particularly of gastric and
pancreatic cancer could, unfortunately, not yet be translated into established therapeutic
strategies [4,5].
Tumoral CCK2 receptors have been found to correspond not only to the wild-type form. A
CCK2 receptor splice variant that has the fourth intron inappropriately retained
(CCK2Ri4sv) has been identified in cancer [6,7]. The molecular basis for this missplicing
event was shown to be a weak 3’ splice site of intron 4 of the CCK2 receptor in association
with reduced splice factor levels [7]. Intron 4 retention leads to insertion of an additional 69
amino acids in the third intracellular loop of the CCK2 receptor protein, a domain important
for signal transduction. Correspondingly, the splice variant was found to differ from the
wild-type CCK2 receptor with respect to activation of intracellular signaling pathways,
while ligand binding characteristics were unchanged [8]: In specific cell types, the
CCK2Ri4sv was constitutively active, leading to increased basal calcium mobilization and
MAP kinase and Src kinase phosphorylation as compared with cells expressing wild-type
CCK2 receptor [6,9,10]. Expression of constitutively active CCK2Ri4sv was associated with
increased basal cell proliferation, and activation of the CCK2Ri4sv by ligand binding
resulted in enhanced cell growth compared with the wild-type receptor [6,8]. A second
aberrant CCK2 receptor form that was identified in cancer, namely in a single case of human
colorectal carcinoma, was a mutant with a single point mutation in the third intracellular
loop [11]. This receptor form also led to increased cell proliferation, was, however, not
associated with a tumorigenic potential as observed for experimental, not naturally occurring
CCK2 receptor mutants [12].
Splice variants with specific expression and functions in cancer such as the CCK2Ri4sv have
been receiving increasing attention because of their possible role in tumor biology and
potential use for diagnostic and/or therapeutic applications [13,14]. One important step
toward a better understanding of their functional or clinical relevance in cancer is the
validation of their expression in human tumor tissues with respect to for instance their tumor
selectivity, frequency, and quantity [15]. As for the CCK2Ri4sv, only selected tumors have
been investigated for this missplicing event so far. While it has been found in colorectal,
pancreatic, and gastric adenocarcinomas as well as in Barrett’s mucosa, a cancer precursor
lesion [6,7,16–18], it has not been quantified in all of these tissues. Moreover, tumors known
for their particularly high CCK2 receptor levels have not been considered for their
CCK2Ri4sv expression. In fact, the molecular mechanisms leading to intron 4 retention may
not be restricted to the tumor types investigated so far, but could occur universally in
cancers expressing the CCK2 receptor.
Therefore, the aim of the present study was to quantitatively characterize the total CCK2
receptor, wild-type CCK2 receptor, and CCK2Ri4sv expression at the transcriptional and
protein level in a broader spectrum of different tumor types using end-point and real-time
reverse transcription-polymerase chain reaction (RT-PCR) and in vitro receptor
autoradiography. It was furthermore intended to assess the cancer selectivity of the
CCK2Ri4sv by including normal tissues of tumor origin in the study. The primary focus was
laid on gastrointestinal and lung tumors, as the CCK2 receptor is a marker for the major
tumors of these organ systems [2].
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Materials and Methods
Tissues
Human tumor and normal tissue samples were obtained from surgical resection specimens,
immediately frozen, and stored at −80°C. A total of 81 tumor samples was investigated,
including 4 insulinomas, 8 ileal carcinoid tumors, 4 GIST, 8 gastric adenocarcinomas, 13
colorectal adenocarcinomas, 7 pancreatic ductal adenocarcinomas, 3 cholangiocellular
carcinomas, 5 hepatocellular carcinomas, 9 SCLC, 12 non-SCLC (nSCLC), and 8
bronchopulmonary carcinoid tumors. Furthermore, 3 samples of each normal gastric
mucosa, gastric muscularis layer, ileal mucosa, colorectal mucosa, pancreas, liver, and lung
were assessed. The tissues originated either from samples investigated previously for
peptide receptors [19–25] collected in accordance with the required international ethical
guidelines or from samples collected prospectively at the Institute of Pathology of the
University of Berne in agreement with the World Medical Association Declaration of
Helsinki, including informed consent and approval by the Institutional Review Board.
In vitro receptor autoradiography for binding sites of CCK2 receptor protein
In vitro receptor autoradiography to assess the expression of CCK2 receptor binding sites in
tumor tissues was performed as described previously [19]. Briefly, 20 µm-thick tissue
sections mounted on glass slides were incubated with 2,000 Ci/mmol of the radioligand 125I-
D-Tyr-Gly-[(Nle28,31)CCK-26–33] (125I-CCK; Anawa, Wangen, Switzerland) either alone
or in competition with 50 nM cold sulfated CCK-8 (Bachem, Bubendorf, Switzerland) or 50
nM cold gastrin (Bachem). Thus, CCK2 receptors can be distinguished from CCK1
receptors, as the former show a high affinity for both CCK-8 and gastrin, whereas the latter
bind only CCK-8 with high affinity. The slides were then exposed to a radiation-sensitive
film. The density of the CCK2 receptor-specific signal on the film was quantified in the
tumor region that was later excised from the original tumor sample for PCR analysis. This
was achieved with a computer-assisted image processing system (Interfocus, Mering,
Germany) and radioactive tissue standards (Autoradiographic [14C] microscales, GE
Healthcare, Little Chalfont, UK) containing known amounts of isotope, cross-calibrated to
tissue-equivalent ligand concentrations [26,27].
RNA extraction and reverse transcription
A tumor region either positive or negative for CCK2 receptor binding sites by
autoradiography was selected and cut out of the frozen tissue block with a sterile scalpel
blade. Care was taken to choose an area of tumor tissue without admixed normal tissue with
the help of a matching H&E-stained tissue section. Similarly, aliquots of normal tissues
were obtained. The dissected tissue samples (≤ 5 mg) were disrupted and homogenized
using the TissueLyser (Qiagen, Hilden, Germany), and total RNA was isolated with the
RNeasy Micro Kit (Qiagen), with inclusion of a DNase I digestion step. The total RNA
concentration was measured by spectrophotometry, and the RNA quality was checked with
the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Reverse
transcription to cDNA was performed with SuperScript III (Invitrogen, Carlsbad, CA) using
oligo(dT)s or random hexamers. For end-point PCR, 500 ng total RNA was converted per
20 µl-volume reaction.
End-point PCR for wild-type CCK2 receptor and CCK2Ri4sv transcripts
CCK2 receptor transcripts were identified with a nested PCR, where the first round reaction
amplified total CCK2 receptor cDNA, and the second round reaction either wild-type CCK2
receptor or CCK2Ri4sv. The primer characteristics are shown in table 1. PCR was carried
out on 2 µl of cDNA or first round PCR product with 5 U/ml Platinum Taq Polymerase
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(Invitrogen), 2 mM MgCl2 (Invitrogen), 0.2 mM dNTPs (Stratagene, La Jolla, CA), and 0.2
µM of both sense and antisense primers in a 50 µl reaction volume. The first round reaction
was cycled 35 times for 30 sec at 94°C, 45 sec at 57°C, and 3 min at 72°C. The second
round reaction included 37 cycles of 30 sec at 94°C, 45 sec at 57°C for the wild-type
receptor or 50 sec at 55°C for the splice variant, and 45 sec at 72°C. Reactions were run at
least in duplicate. As positive controls, the previously described CHO cell lines stably
expressing wild-type CCK2 receptor (CHO-CCK2R cells) or CCK2Ri4sv (CHO-CCK2R-i4
cells) [8] were used, and for negative control no template was added. Furthermore, β-actin
control PCR reactions were run for each sample with 32 cycles comprising 30 sec at 94°C,
45 sec at 59°C, and 1 min at 72°C (table 1). Fifteen µl-fractions of final PCR products were
resolved on a 1.5% agarose/TAE gel along with a 100 bp DNA Ladder (New England
Biolabs, Ipswich, MA) as molecular weight marker and visualized by ethidium bromide
staining. Representative bands were excised and sequenced to confirm their identities.
Real-time PCR for total CCK2 receptor and CCK2Ri4sv transcripts
Of 52 of the 63 tumors positive for CCK2 receptor transcripts by end-point PCR, sufficient
RNA was available for further real-time PCR analysis. Two different real-time PCR
reactions were established to amplify either total CCK2 receptor or CCK2Ri4sv cDNA.
Primers and the TaqMan MGB probe (table 1) were designed using the Primer Express
software version 3.0 (Applied Biosystems, Foster City, CA) and synthesized by Applied
Biosystems. The optimal primer and probe concentrations yielding the lowest Ct and highest
ΔRn values for a given RNA concentration were found to be 900 nM for all primers and 250
nM for the probe. Using these concentrations, cDNA corresponding to 100ng total RNA was
amplified in a 20 µl reaction volume with the TaqMan Universal PCR Master Mix (Applied
Biosystems) on a 7900HT Fast Real-time PCR System (Applied Biosystems) as follows: 2
min at 50°C, 10 min at 95°C, followed by 50 cycles of 15 sec at 95°C and 1 min at 60°C.
The endogenous control genes 18S rRNA, GAPDH, and human β-actin were amplified in
each sample using pre-designed primer and probe sets by Applied Biosystems. Standard
curves for all genes were constructed using serial cDNA dilutions of CHO-CCK2R or CHO-
CCK2R-i4 cells or the pancreatic cancer cells CAPAN2 or BxPC3 (American Type Culture
Collection, Manassas, VA). On each plate, the same CCK2 receptor expressing tumor was
included as calibrator, and no template reactions as negative controls. All reactions were run
at least in triplicate.
CCK2 receptor gene expression was relatively quantified using the efficiency (E)-corrected
ΔCt method. Total CCK2 receptor transcript levels were expressed relative to 18S rRNA and
a calibrator sample using the equation:
CCK2Ri4sv transcript expression was reported relative to total CCK2 receptor transcript
expression as follows:
Immunohistochemistry for the proliferation marker MIB-1
Immunohistochemistry for the proliferation marker MIB-1 was performed on 9 SCLC, 4
nSCLC, and 4 pancreatic adenocarcinomas. Cryostat sections (10 µm thick) were postfixed
in formalin. The primary antibody (DAKO, Zug, Switzerland) was added in a 1:50 dilution.
The secondary antibody was a biotinylated goat anti-mouse immunoglobulin (Dako).
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Antibody binding was visualized using the VECTASTAIN Elite ABC kit (Vector,
Burlingame, CA). Staining was carried out with DAB, and counterstaining with hemalum.
Statistical analysis
Statistical analysis was performed with the GraphPad Prism software version 4.0 (La Jolla,
CA), using the unpaired t-test, Mann-Whitney test, linear regression analysis and Spearman
correlation. P<0.05 was considered statistically significant.
Results
Real-time PCR: specificity, dynamic range, normalization
Several lines of evidence of the specificities of the real-time PCR reactions for total CCK2
receptor and the CCK2Ri4sv, respectively, were obtained. By separating amplification
products on an agarose gel, each reaction yielded a single band migrating with the expected
molecular size (figure 1A). Moreover, the reaction for CCK2Ri4sv produced no
amplification signal in CHO-CCK2R cells which express only wild-type, but not splice
variant CCK2 receptor. Finally, in samples where the reverse transcriptase had been omitted,
no amplification signal was obtained.
The real-time PCR assays for total and splice variant CCK2 receptors were tested on serial
cDNA dilutions of CHO-CCK2R and CHO-CCK2R-i4 cells, respectively. In both assays, the
relationship between the Ct values, which spanned the Ct values anticipated for the samples,
and the logarithm of the starting RNA amount remained linear over the tested 6-log
concentration range (figure 1B). Similar plots were created for 18S rRNA, GAPDH, and β-
actin, yielding slopes of −3.40, −3.39, and −3.50, respectively, and r2>0.99 for all three
genes. These plots were then generated in each real-time PCR run, to calculate the
efficiencies used for relative quantification.
The endogenous control genes 18S rRNA, GADPH, and β-actin were evaluated for their
suitability for normalization, while a larger number of candidate genes could not be tested
due to limited availability of sample RNA. The expression levels of these genes were
determined in each sample using the formula E−Ct. 18S rRNA expression was fairly
constant among the various tumor groups, whereas expression of GAPDH and β-actin was
much more variable. We concluded that 18S rRNA was the most suitable endogenous
control in the studied tumor population and, therefore, used it for relative quantification of
total CCK2 receptor transcript levels.
Wild-type CCK2 receptor transcript expression
The wild-type CCK2 receptor transcript expression was assessed with end-point PCR. It was
found to be very common (table 2). It was detected in every tumor type studied, except for
cholangiocellular carcinoma. Moreover, the frequency of the wild-type CCK2 receptor
transcript expression in the individual tumor types was mostly high. Furthermore, all
investigated normal tissues were positive for the wild-type CCK2 receptor except for the
lung. Typical end-point PCR results for the wild-type CCK2 receptor in tumors and normal
tissues are shown in figure 2A in the top gel.
CCK2Ri4sv transcript expression
Using end-point PCR, CCK2Ri4sv transcripts were found in a subset of tumors expressing
wild-type CCK2 receptor mRNA, while they were not detected in tumors without wild-type
receptors. Unlike the wild-type form, the splice variant was restricted to specific tumor types
(table 2, figure 2A). It was commonly expressed in insulinomas, GIST, and SCLC. Indeed,
in the former two tumor types it was present in every case studied. By contrast, the
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CCK2Ri4sv expression was rare in pancreatic adenocarcinomas and nSCLC, where only
single cases were found to be positive. Splice variant transcripts were not identified in the
remaining tumors. Likewise, they were not detected in any of the normal tissue samples.
In the tumors that expressed the CCK2Ri4sv by end-point PCR, the transcript levels were
quantified relative to total CCK2 receptor levels with real-time PCR. Splice variant
transcripts were found to account for a very small fraction of all CCK2 receptor transcripts.
The mean expression levels ranged from 0.21‰ of total CCK2 receptors in GIST to 1.05‰
in SCLC (table 2). The expression levels in the individual cases are shown in figure 3A.
This figure also demonstrates how the relative splice variant amounts varied between the
different tumor types. In SCLC, a significantly higher proportion of all CCK2 receptor
transcripts corresponded to the splice variant than in GIST (p=0.0003) or insulinomas
(p=0.0045).
Real-time PCR analysis furthermore revealed that the identification of the CCK2Ri4sv was
associated with the amount of total CCK2 receptor mRNA. Tumors with splice variant
expression showed significantly higher total receptor transcript levels than tumors without
(p<0.0001). This is shown in figure 3B for the individual cases. The splice variant was
identified only in tumors with total CCK2 receptor mRNA levels above a certain level.
Conversely, in only two of the 37 tumors without splice variant expression, the total CCK2
receptor mRNA amounts equaled those of tumors expressing the splice variant, while the
remaining tumors showed lower total receptor transcripts levels.
Immunohistochemistry for the proliferation marker MIB-1 was performed in selected tumor
samples to assess the relation between CCK2Ri4sv expression and the proliferative index. In
SCLC, the mean proportion of tumor cells in the proliferative phase, as visualized by
nuclear staining for MIB-1, was larger in tumors with than in tumors without CCK2Ri4sv
expression (64.8% MIB-1-positive tumor cells in SCLC with CCK2Ri4sv expression vs.
56.5% in SCLC without CCK2Ri4sv expression). This difference was, however, not
statistically significant (p=0.2774). Conversely, in nSCLC and pancreatic adenocarcinomas,
the single cases expressing CCK2Ri4sv exhibited a lower proliferative index than the tumors
without splice variant expression (nSCLC: 30.5% vs. mean 37.7% MIB-1-positive tumor
cells; pancreatic adenocarcinomas: 9% vs. mean 30.1%).
Total CCK2 receptor binding site expression
Total CCK2 receptor protein expression in tumor tissues was assessed on the basis of CCK2
receptor binding with in vitro receptor autoradiography [19]. With this method, the binding
sites of both wild-type CCK2 receptors and CCK2Ri4sv are simultaneously identified, as
these two receptor forms cannot pharmacologically be differentiated [8]. The
autoradiography results were comparable with published data (table 2) [2]: The CCK2
receptor binding site expression with respect to both incidence and density was particularly
high in insulinomas, GIST, and SCLC, but virtually absent in gastric, colorectal, and
pancreatic carcinomas, liver tumors, and nSCLC. This is illustrated with two representative
cases in figure 2B. The GIST in the first row displays strong 125I-CCK binding,
corresponding to a high number of CCK receptor binding sites; displacement of 125I-CCK
by both CCK-8 and gastrin provides proof of specific CCK2 receptor identification.
Conversely, in the colorectal carcinoma in the second row there are no CCK receptor
binding sites identifiable, as this tumor shows no specific 125I-CCK binding.
Correlation of CCK2 receptor binding site and transcript expression in tumor tissues
Receptor binding sites were not identified in over half of the tumors showing CCK2 receptor
transcripts (table 2). Real-time PCR analysis revealed that these autoradiographically
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negative tumors showed particularly low total CCK2 receptor transcript levels, while tumors
with detectable receptor binding sites displayed significantly higher receptor mRNA
amounts (p<0.0001). This is demonstrated for the individual tumors in figure 3B.
Furthermore, it was found that in autoradiographically positive tumors the actual binding
site density deviated considerably from that predicted from the transcript levels in a linear
regression model in the majority of cases, as can be seen in figures 4A and B. Taking into
account all autoradiographically positive and negative cases, the density levels of CCK2
receptor binding sites correlated statistically fairly well with total CCK2 receptor transcript
levels (r2=0.6579, p=0.0002).
Discussion
The CCK2 receptor splice variant with intron 4 retention was previously described in a
limited number of colorectal, pancreatic, and gastric adenocarcinomas [6,7,16,17]. It was
considered to be important in these particular tumors, due to its special functional
characteristics, namely constitutive activity associated with increased proliferation [6]. By
quantitatively assessing the CCK2Ri4sv expression in a larger number of gastrointestinal
and lung tumors, the present study reveals that this splice variant is in fact a marker of a
different spectrum of tumors. It was found in several tumor types that up to now have not
been considered for this splicing event, including such diverse tumors as insulinomas, GIST,
SCLC, and nSCLC. In most of these tumors the CCK2Ri4sv was expressed in high
frequency, whereas it was rare or not detected in colorectal, pancreatic, and gastric
adenocarcinomas. The CCK2Ri4sv was never the only CCK2 receptor form present in the
tumors. Indeed, it accounted for only a small fraction of all CCK2 receptor transcripts. The
occurrence of the CCK2Ri4sv was strongly associated with elevated total CCK2 receptor
mRNA levels. This is suggestive of an intrinsic small likelihood of intron 4 not to be
recognized by the splicing machinery due to its weak 3’ splice site [7] which reaches
detection levels when enough CCK2 receptor is transcribed. Conversely, the significant
differences in the relative CCK2Ri4sv expression levels observed between the various tumor
types indicate additional tumor-specific aberrant molecular processes involved in
missplicing of the CCK2 receptor. The tumoral CCK2Ri4sv expression was not significantly
associated with an increased proliferation rate.
Existing data indicate a high selectivity of the CCK2Ri4sv for tumors over non-neoplastic
tissues, which is in fact much higher than that of the wild-type CCK2 receptor
[6,7,16,17,31]. In the present series, the CCK2Ri4sv was not identified in a variety of
normal gastrointestinal and lung tissues. It was in particular not detected in normal tissues of
origin of tumors that frequently express it, such as gastric muscularis and lung. This extends
previous findings of the absence of CCK2Ri4sv in normal colon and pancreas [6,7,16]. Of
note, the CCK2Ri4sv may not absolutely be restricted to neoplasia, as it has been described
in peripheral blood mononuclear cells of a minority of healthy individuals and in normal
gastric mucosa [17,31].
For some tumor and normal tissues, discrepancies exist between various reports concerning
the presence of CCK2Ri4sv mRNA. Colorectal cancer was originally reported to express
CCK2Ri4sv, but not wild-type CCK2 receptor transcripts [6]. However, Schmitz et al.
recognized only the wild-type, but not the splice variant receptor in as many as 79 colorectal
carcinomas [11], in full agreement with our present findings. Furthermore, we could not
detect the CCK2Ri4sv in gastric cancer or normal gastric mucosa where it had been
described before [17]. Finally, the single cases of CCK2Ri4sv-expressing pancreatic
adenocarcinomas reported in the literature suggested frequent CCK2 receptor missplicing in
these tumors [7,16]. However, in this study the splice variant could be identified in only one
out of eight investigated cases. This variable identification of CCK2Ri4sv transcripts may at
Körner et al. Page 7
J Cell Mol Med. Author manuscript; available in PMC 2011 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
least in part be due to the very low expression levels. The amount of RNA employed for RT-
PCR could become critical. Zhou et al. used ten times more RNA than we were able to
utilize [17]. Furthermore, primers may underperform in amplification of low abundant
transcripts when located in the vicinity of AG-rich stretches [32] which are present in intron
4 of the CCK2 receptor. On the other hand, it has to be considered that primers not able to
distinguish between amplified cDNA and genomic DNA [6,16] may be responsible for a
false high incidence of splice variants with intron retention.
Divergent data has also accumulated over the last years on the CCK2 receptor protein and
transcript expression in gastrointestinal tumors, in particular in colorectal, pancreatic, and
gastric adenocarcinomas [5]. In these tumors, the CCK2 receptor incidence was considerably
lower when assessed with receptor binding studies compared with RT-PCR. In the present
study, both methods were for the first time applied in parallel on the same tumor specimens,
and the quantitative expression of total tumoral CCK2 receptor binding sites was correlated
with that of total CCK2 receptor mRNA. This revealed that the cases with divergent results,
i.e. negative autoradiography but positive RT-PCR, consistently expressed very low
amounts of total CCK2 receptor transcripts. This may reflect a lower sensitivity of CCK2
receptor autoradiography compared with RT-PCR. The correlation furthermore
demonstrated that CCK2 receptor transcript levels could not reliably predict the amounts of
CCK2 receptor binding sites in a substantial number of cases. Possible explanations for this
non-linear relationship between CCK2 receptor mRNA and protein levels are for instance
variations in the protein translation rate or in the compartmentalization of the receptor
protein in intracellular pools [33] between individual tumors.
The protein expression of the CCK2Ri4sv cannot specifically be assessed in tissues, as
selective ligands or immunohistochemical antibodies are not available. In transfected cell
lines, it could, however, be shown that the CCK2Ri4sv translated into protein to a similar
extent as the wild-type receptor [8]. If this also holds true for original tumors can only be
speculated at present. In this case, the density levels of total CCK2 receptor binding sites,
which most probably correspond largely to wild-type receptors, would suggest very low
CCK2Ri4sv protein amounts in tumors. It has to be considered, though, that the splice
variant protein may not show the same stability or be expressed to the same extent in the
plasma membrane as the wild-type receptor. Indeed, in transfected cell lines the CCK2Ri4sv
was found to be located mainly in the intracellular compartment, whereas the wild-type
receptor was expressed predominantly in the cell membrane [34].
The CCK2Ri4sv has been shown to stimulate cell proliferation in vitro [6,7,9,35]. In the
present study, however, CCK2Ri4sv-expressing tumors did not show a significantly
increased proliferation rate compared with tumors without the splice variant, although the
number of investigated cases may be too small to permit definite conclusions. At present, it
remains unclear in how far the functional effects of CCK2Ri4sv observed in vitro may be
extrapolated to original tumors. It has in particular to be considered that the CCK2Ri4sv
expression in its natural environment may show significant differences to that in
experimental models. Indeed, transfected cell lines used to explore CCK2Ri4sv functionality
express the splice variant abundantly and selectively [6,7,35], while original tumor tissues
express CCK2Ri4sv transcripts at very low levels and always together with high levels of
wild-type CCK2 receptor and sometimes even CCK1 receptors [2]. In vivo, the CCK2Ri4sv
may well dimerize with either of these receptors, similar to the wild-type CCK2 receptor
[36]. Would such heterodimers behave in terms of receptor binding and signaling more like
wild-type CCK2 or CCK1 receptors than like the CCK2Ri4sv, or would they elicit even new
characteristics? Moreover, as CCK2Ri4sv is expressed at very low levels in original tumors,
it may not contribute to cell proliferation to the same extent as in the cell line models.
Finally, the constitutive activity of the CCK2Ri4sv, which is largely responsible for the
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increased proliferation, may not be present in all original tumors. In fact, it was found to be
restricted to certain cell types and to be in particular absent in epithelial tumor cells [7,9]. A
possible strategy to further elucidate CCK2Ri4sv-mediated biologic effects may be to study
the association between CCK2Ri4sv expression and proliferative index or activation of
down-stream signaling pathways in an extended number of original tumors. Unfortunately,
the use of cancer cell lines as an alternative to transfected cell lines for similar studies is
limited, since cancer cell lines exhibit splicing patterns that are significantly different from
those occurring in vivo and have often lost splice variant expression [9,15,18,37] (personal
observations).
Given its high specificity for and high incidence in clinically important tumors like SCLC
and GIST, the CCK2Ri4sv may represent an attractive target for potential clinical
applications [13,14]. The low tumoral CCK2Ri4sv expression levels imply that only
diagnostic tests with high sensitivity, such as PCR, may be clinically useful. Indeed, it has
been demonstrated with several examples that PCR for splice variants performed for
instance on pleural or peritoneal fluid can assist in tumor diagnosis, despite the very high
sensitivity of the method and not exclusive expression of splice variants in cancer cells [38–
40]. Conversely, targeting CCK2Ri4sv with a radioactive ligand, as suggested recently [41],
may be a less promising approach because accumulation of sufficient radioactivity within
the tumor area for imaging or therapy may not be achieved due to the low tumoral
CCK2Ri4sv expression levels.
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Figure 1.
Real-time PCR: specificities (A) and dynamic ranges (B) of total CCK2 receptor and
CCK2Ri4sv assays. A: Visualization of real-time PCR products obtained for total CCK2
receptor and CCK2Ri4sv in CHO-CCK2R and CHO-CCK2R-i4 cells, respectively, as well
as in an insulinoma expressing both wild-type and splice variant CCK2 receptor in an
agarose gel. A 100bp DNA ladder was included as molecular weight marker. Both PCR
assays yield a single product migrating with the expected size. B: Standard curves of total
CCK2 receptor and CCK2Ri4sv real-time PCR reactions. Both curves show linearity over a
6-log RNA concentration range.
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Figure 2.
Expression of CCK2 receptor transcripts (A) and binding sites (B) in tissues. A: Agarose
gels showing representative end-point RT-PCR products for wild-type CCK2 receptor (top
gel), CCK2Ri4sv (middle gel), and β-actin (bottom gel) in tumors and normal tissues.
Positive control reactions were performed on cDNA of CHO-CCK2R and CHO-CCK2R-i4
cells for the wild-type and splice variant CCK2 receptor, respectively. For negative control
no template was added (H2O only). A 100bp DNA ladder served as molecular weight
marker. Wild-type CCK2 receptor transcripts are amplified in all displayed tumors and
normal tissues except for normal lung. Note the weak bands obtained in gastric, colorectal,
and hepatocellular carcinomas. In the colon mucosa, the band is barely visible. CCK2Ri4sv
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transcripts are detected in the GIST, insulinoma, pancreatic adenocarcinoma, SCLC, and
nSCLC, but not in the remaining tumors or normal tissues. Additional bands migrating with
higher molecular weights correspond to amplified genomic CCK2 receptor or are non-
specific, as confirmed by sequencing. B: In vitro receptor autoradiography on serial tissue
sections to assess CCK receptor binding sites in a GIST (a–d) and a colorectal
adenocarcinoma (e–h). a, e: H&E-stained tissue sections showing the tumor tissues (bars =
1mm). b, f: Autoradiograms showing total 125I-CCK binding to the tumor tissues. Very
strong 125I-CCK binding to the GIST, but hardly any labeling of the colorectal carcinoma. c,
g: Autoradiograms showing 125I-CCK binding in the presence of 50 nM cold CCK-8; and e,
h: autoradiograms showing 125I-CCK binding in the presence of 50 nM cold gastrin. In the
GIST, 125I-CCK is completely displaced by CCK-8 and almost to the same extent by
gastrin, proving that the vast majority of the 125I-CCK binding sites correspond to CCK2
receptors. (The small fraction of total 125I-CCK binding that is displaced by CCK-8 but not
gastrin corresponds to concomitantly expressed CCK1 receptors.) Conversely, in the
colorectal carcinoma, the traces of 125I-CCK binding are not displaced by either CCK-8 or
gastrin, proving that they reflect non-specific 125I-CCK binding to the tissue. This tumor has
no detectable CCK receptor binding sites.
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Figure 3.
CCK2Ri4sv transcript expression in tumors. A: Real-time PCR quantification of CCK2Ri4sv
transcripts relative to total CCK2 receptor transcripts. Each point represents an individual
tumor; scale bars = mean values. In all tumors, the CCK2Ri4sv transcripts account for a
small fraction in the per mill range of total CCK2 receptor transcripts. SCLC and nSCLC
express significantly higher relative amounts of CCK2Ri4sv transcripts than insulinomas or
GIST. B: Total CCK2 receptor transcripts levels relative to 18S rRNA levels in tumors with
CCK2Ri4sv expression (black points) and without CCK2Ri4sv expression (white points), as
well as in autoradiographically positive tumors (large points) and autoradiographically
negative tumors (small points). Total CCK2 receptors could not be quantified in a GIST and
a SCLC because 18S rRNA levels strongly deviated from expected values in the former and
not enough RNA was available for endogenous control gene PCR in the latter. The
CCK2Ri4sv is identified only in tumors with relative total CCK2 receptor levels above 1,
whereas almost all tumors without CCK2Ri4sv expression show total receptor transcript
levels below 1. Furthermore, most of the tumors without autoradiographically measurable
CCK2 receptor binding sites exhibit very low total receptor transcript levels, whereas the
tumors with identifiable receptor binding sites express higher transcript levels.
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Figure 4.
Correlation of the CCK2 receptor binding site density measured with autoradiography with
receptor transcript levels relative to 18S rRNA levels assessed by real-time PCR in
autoradiographically positive tumors. B is a higher magnification of the area indicated with
dotted lines in A. The straight line represents the line of best fit obtained by linear regression
analysis (dashed lines = 95% confidence intervals).
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